All In Biotech

Drug Trial Radar · NCT06718686

Rifaximin SSD in Dementia Trial

Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Oct 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Jasmohan BajajFederal agency
Sponsor type
Federal agency
Collaborators
Bausch Health Americas, Inc.
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

Conditions

  • Dementia Alzheimer Type
  • Dementia Associated With Cerebrovascular Disease

Interventions

  • Rifaximin SSD 40 mg IR tabletDrug

    Drug therapy vs placebo

  • PlaceboDrug

    Placebo drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in stool and serum short-chain fatty acid levelsTime frame: 10 weeks
  2. Change in bile acids in stool and serumTime frame: 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Richmond VA Medical Center

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.